One-step cleavage and purification: a bifunctional IdeS-Protein A fusion protein for on-column generation of antibody fragments Authors: Tongsheng Zhang, Huayuan Liao, Chun-Bo Teng, Chao Wang Published: 2026 ABSTRACT ABSTRACTConventional production of antibody fragments (e.g. Fab/F(ab′)2, VHH/(VHH)2) involves sequential enzymatic cleavage and multi-step purification to remove Fc domains and residual enzymes, a process that is laborious and inefficient for small-scale workflows. To address this, we engineered a bifunctional IdeS-Protein A (IPA) fusion protein, which combines the specific IgG-cleaving activity of IdeS with the Fc-binding capability of Protein A. In solution, this construct enabled simultaneous antibody cleavage and affinity-mediated removal of both the enzyme and Fc fragments in a single step. Furthermore, we immobilized the fusion protein on a chromatographic resin to create an integrated “on-column cleavage-purification” platform. This system allows antibody capture, in-situ cleavage, and direct collection of high-purity F(ab′)2 fragments from the flow-through, while Fc fragments, uncleaved antibodies, and the enzyme are retained on the column. This work establishes a streamlined, one-step method for generating antibody fragments, offering a robust and automatable platform for research and preclinical applications. Introduction Monoclonal antibodies, nanobodies (variable domain of heavy chain of heavy-chain antibodies, VHH), and antibody-derived domains such as Fabs (antigen-binding fragments) are fundamental tools used in biomedical research and key modalities for therapeutic development.1 During early research and preclinical phases, the rapid generation of highly pure and homogeneous antibody fragments, including Fab/F(ab′)2 and VHH/(VHH)2, is critical for functional screening, structural characterization, and formulation design.2 Conventional methods typically involve enzymatic cleavage of full-length antibodies followed by multistep chromatographic purification, often including Protein A affinity capture, ion-exchange, and size-exclusion chromatography (SEC), to separate target fragments from Fc domains and uncleaved antibodies.3,4 These workflows are not only labor-intensive and time-consuming, but also frequently suffer from low yields and batch-to-batch variability, creating a notable bottleneck for rapid, small-scale fragment generation.5 IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) is a highly specific cysteine protease that cleaves IgG below the hinge region, efficiently converting an intact IgG molecule into one F(ab′)2 fragment and one Fc homodimer.5,6 This specificity makes IdeS an attractive enzymatic tool for antibody fragment production. Nevertheless, conventional cleavage workflows require additional and often complex purification steps to remove residual IdeS, generated Fc fragments, and any remaining intact antibodies before homogeneous F(ab′)2/(VHH)2 or monomeric Fab/VHH fragments can be obtained.7 To overcome these limitations, we designed a novel bifunctional IdeS-Protein A (IPA) fusion protein. The design capitalizes on synergistic domain functions: 1) the Protein A domain confers specific, high-affinity binding to the Fc region of antibodies, positioning the target for efficient cleavage; 2) the IdeS domain retains full cleavage activity, enabling precise hydrolysis of the hinge region of the bound antibody8; and (3) the Protein A domain further complexes with Fc fragments or any residual full-length IgG, allowing simultaneous removal of these components along with the immobilized enzyme in a single affinity-based purification step.9 Building on this bifunctional construct, we further developed an integrated purification strategy by immobilizing the IPA fusion protein as an affinity ligand on a chromatographic support, thereby establishing a novel “on-column cleavage-purification” system. In this design, when a sample containing full-length antibodies is applied, antibodies are captured and concentrated on the column via Fc-Protein A interaction. Subsequently, the adjacent immobilized IdeS domains perform in situ cleavage of the bound antibodies, releasing target F(ab′)2 fragments into the flow-through, which can be collected directly or further processed to generate Fab/VHH. Finally, a single elution step removes the Fc fragments and any uncleaved antibodies that are retained on the column via Protein A binding, yielding high-purity antibody fragments and eliminating the need for separate enzyme removal or additional polishing steps. In this study, we detail the design, recombinant expression, and purification of the fully active IPA fusion protein and validate its dual functionality through comprehensive activity assays, including binding affinity measurements and cleavage kinetics. We further demonstrate the practical utility of this protein by immobilizing it as a functional ligand to establish a novel integrated chromatography platform that enables direct, one-step generation of high-purity F(ab′)2 fragments from complex mixtures. This work not only offers an efficient, straightforward, and automatable platform for small-scale antibody fragment generation, but also illustrates the potential of rational design of multifunctional enzyme-fusion proteins for developing advanced separation media. Results Design and preparation of the IPA fusion protein A ternary complex of a human IgG Fc fragment bound to both the Protein A B domain (PAB) and IdeS (Figure 1A) was modeled based on the crystal structures of the PAB-Fc (PDB: 1FC2) and IdeS-Fc (PDB: 8A47) complexes.10,11 Since PAB may bind to either of the two arms of the Fc region, two PAB molecules are depicted in the figure. Structurally, the binding sites of IdeS and PAB on the Fc do not overlap. Specifically, IdeS primarily interacts with the N-terminal region of the CH2 domain, while PAB binds predominantly to the elbow hinge located between the CH2 and CH3 domains. Notably, the modeled ternary complex reveals a substantial spatial separation between the C-terminus of IdeS and the N-termini of the two PAB molecules, with a measured distance of approximately 70–80 Å. To accommodate this spatial constraint and enable the functional fusion of both proteins while retaining their capability for in situ cleavage of the same IgG molecule, a (GGGGA)4 flexible linker was introduced between the two domains (Figure 1B). The Z domain, derived from the B domain of Staphylococcus aureus Protein A, was utilized as the Fc-binding module in the construction of the IdeS fusion protein.12 To facilitate purification, a polyhistidine tag was appended to the C-terminus. The resulting fusion protein was successfully expressed in Escherichia coli (E. coli) and purified via Ni-NTA affinity chromatography followed by SEC, yielding a product of high purity (Figure 1C). Mass spectrometric (MS) analysis confirmed that the molecular weight of the purified protein corresponded to the theoretical value of IPA, and indicated cleavage of the N-terminal methionine by endogenous methionine aminopeptidase (Figure 1C). Figure 1.Design and preparation of IPA. (A) Overall view of the complex of Fc with IdeS and Protein A. (B) Domain architectures of IPA. (C) SDS-PAGE, SEC and MS analysis of E. coli expressed IPA. Lane M, marker; lane 1, whole cell; lane 2, pellets; lane 3, supernatants; lane 4, purified IPA.A shows a ternary complex model of human IgG Fc, Protein A B domain, and IdeS. Fig 1B illustrates the domain architecture of IPA, where the N-terminal IdeS and C-terminal Protein A are linked by a (GGGGA)4linker. Fig 1C presents SDS-PAGE results showing a purified IPA band at around 41 kDa, SEC results demonstrating high purity, and MS results confirming that the measured molecular weight matches the theoretical value. Design and preparation of IPA. (A) Overall view of the complex of Fc with IdeS and Protein A. (B) Domain architectures of IPA. (C) SDS-PAGE, SEC and MS analysis of E. coli expressed IPA. Lane M, marker; lane 1, whole cell; lane 2, pellets; lane 3, supernatants; lane 4, purified IPA. Functional evaluation of IPA The cleavage site of IdeS is located within the lower hinge region, specifically between the Gly-Gly or Ala-Gly residues (Figure 2A), and its sensitivity varies among different IgG subclasses.4,13 The cleavage activity of IPA was evaluated in parallel with IdeS using adalimumab as substrate. Antibody-enzyme incubation at a 100:1 molar ratio for 1 h yielded reaction mixtures, which were subsequently analyzed by capillary electrophoresis sodium dodecyl sulfate (CE-SDS). CE-SDS showed complete antibody cleavage by both enzymes, indicated by the exclusive presence of F(ab′)2 and Fc peaks (Figure 2B). To assess cleavage breadth, activity against additional IgG subclasses and species (human IgG2, human IgG4, and mouse IgG2a) was examined using CE-SDS (Figure S1-S9). IPA cleaved all tested IgGs with efficiency comparable to IdeS (Figure 2C). Specifically, it achieved complete cleavage of hIgG4 and an efficiency of 59% for hIgG2. In contrast, it showed lower sensitivity to mIgG2a, with the current cleavage conditions yielding less than 10% cleavage efficiency. Figure 2.Functional evaluation of IPA. (A) IdeS cleavage sites for hIgg1, hIgg2, hIgg4 and mIgg2a. (B) CE-SDS analysis comparing intact adalimumab with the products generated by cleavage using IdeS and IPA separately. (C) Cleavage activity of IdeS and IPA against hIgg2, hIgg4 and mIgg2a. (D) BLI analysis of the binding and dissociation of adalimumab to Protein A, IPA, and IdeS-4 Protein A.A shows the IdeS cleavage site within the lower hinge region, located between the Gly-Gly or Ala-Gly residues. Fig 2B presents CE-SDS results demonstrating that after cleavage with IdeS or IPA using adalimumab as substrate, only F(ab′)2and Fc peaks are present. Fig 2C shows that IPA cleaves human IgG2, IgG4, and mouse IgG2a with efficiency comparable to IdeS, and both enzymes exhibit lower sensitivity to mouse IgG2a. Fig 2D shows BLI results of Fc-binding activity for individual Protein A and IPA. Due to its monovalent architecture, IPA shows a lower binding affinity than individual Protein A, which contains four tandem B domains. However, the variant IdeS-4×Protein A shows a KD close to that of individual Protein A. Functional evaluation of IPA. (A) IdeS cleavage sites for hIgg1, hIgg2, hIgg4 and mIgg2a. (B) CE-SDS analysis comparing intact adalimumab with the products generated by cleavage using IdeS and IPA separately. (C) Cleavage activity of IdeS and IPA against hIgg2, hIgg4 and mIgg2a. (D) BLI analysis of the binding and dissociation of adalimumab to Protein A, IPA, and IdeS-4 Protein A. The Fc-binding activity of the Protein A domain within the fusion construct was evaluated by bio-layer interferometry (BLI). IPA exhibited high-affinity binding with a bivalent dissociation constant (KD) of 5.5 × 10−9 M (Figure 2D). Due to its monovalent architecture, the fusion protein displayed faster dissociation kinetics than individual Protein A (four tandem B domains). To verify that the observed binding disparity is attributable to the valency of domain B, we engineered a construct termed IdeS-4 Protein A. This variant, consistent with individual Protein A, comprises four tandem B domains. BLI analysis demonstrates that the binding kinetics and KD of IdeS-4 Protein A are comparable to those of the individual protein A. Collectively, these data demonstrate that IPA retains both the cleavage activity of IdeS and the Fc-binding capability of Protein A, supporting its suitability for integrated enzymatic cleavage and affinity-based purification. Stability evaluation of IPA as an affinity chromatography ligand To enable one-step antibody fragment generation, we assessed the feasibility of using IPA as a ligand for affinity chromatography resin, allowing simultaneous on-column cleavage and purification. First, the stability of IPA under low-pH conditions was evaluated. The protein was incubated in 50 mM sodium acetate-acetic acid (NaAc-HOAc) elution buffer (pH3.4) at room temperature for 30 min, then buffer-exchanged to 20 mM Tris, 50 mM NaCl (pH 7.4). Enzymatic activity was subsequently tested again. CE-SDS analysis (Figure 3) showed that the intact adalimumab peak disappeared completely, replaced by characteristic F(ab′)2 and Fc peaks, confirming complete cleavage. The low-pH-treated sample retained high enzymatic activity, validating its suitability as a resin ligand. Figure 3.CE-SDS analysis of adalimumab following cleavage with low pH-treated IPA.shows CE-SDS analysis of adalimumab after cleavage with low pH-treated IPA; the intact adalimumab peak disappears completely and is replaced by characteristic F(ab′)2and Fc peaks, confirming complete cleavage. CE-SDS analysis of adalimumab following cleavage with low pH-treated IPA. One-step antibody fragment generation An engineered cysteine residue was introduced at the C-terminus of the immunoglobulin protease (IPA) to facilitate site-specific covalent immobilization onto chromatography media. Following the assembly of the affinity column, its performance in on-column antibody fragmentation was assessed using adalimumab as a model IgG. A sample of adalimumab (2 mg at 0.5 mg/mL) was loaded onto the column at a flow rate of 0.2 mL/min. The flow-through fraction was collected and subsequently the column was washed with elution buffer and the eluate was collected. Analysis of the flow-through by SEC-HPLC revealed a predominant peak corresponding to F(ab′)2 fragments, demonstrating efficient on-column cleavage and the successful single-step isolation of the target product (Figure 4). From this run, 0.85 mg of F(ab′)2 fragments was obtained, representing a yield of 65%. The residual F(ab′)2 fragments retained on the resin were attributed to weak interactions between VHH and the Protein A of immobilized IPA. The elution fraction contained both Fc and F(ab′)2 fragments, with no intact IgG detected, confirming the completeness of the enzymatic cleavage (Figure 4). Figure 4.On-column generation of F(ab′)2 fragments. SEC analysis of loaded adalimumab (black), along with its corresponding flow-through (blue) and eluate (red).shows HPLC results of flow-through and eluate fractions when using IPA resin for on-column F(ab′)2fragment generation. The flow-through contains a predominant peak corresponding to F(ab′)2fragments. Fc fragments are the main components in the eluate, along with a small amount of residual F(ab′)2fragments. On-column generation of F(ab′)2 fragments. SEC analysis of loaded adalimumab (black), along with its corresponding flow-through (blue) and eluate (red). Subsequently, to evaluate the recyclability of the packing material, the loading and elution process for adalimumab was repeated for five consecutive cycles (Figure 5A). The content and purity of the collected F(ab′)2 fragments were recorded for each cycle. SEC analysis confirmed that high-purity F(ab′)2 fragments were obtained throughout all five cycles (Figure 5B and S10). In addition, the experimental yield of F(ab′)2 fragments remained at a stable level, fluctuating between 65% and 76% (Figure 5B). These minor variations are likely attributable to differences in digestion efficiency and sample handling, and the observed yields remain within an acceptable range for this purification process. Figure 5.Consecutive on-column generation of high-purity F(ab′)2 fragments. (A) Loading and elution profile of adalimumab using an IPA column chromatography system. (B) Experimental yield and purity of F(ab′)2 fragments for each cycle.demonstrates the recyclability of IPA resin. Fig 5A shows five consecutive loading and elution cycles for adalimumab, recording the content and purity of collected F(ab′)2fragments per cycle. Fig 5B presents SEC analysis confirming high-purity F(ab′)2fragments across all five cycles (above 96%), with experimental yields remaining stable between 65% and 76%. Consecutive on-column generation of high-purity F(ab′)2 fragments. (A) Loading and elution profile of adalimumab using an IPA column chromatography system. (B) Experimental yield and purity of F(ab′)2 fragments for each cycle. Discussion In this study, we report the rational design and validation of IPA, a bifunctional IdeS-Protein A fusion protein that integrates antibody cleavage and affinity capture into a single molecular entity, enabling streamlined, one-step generation of antibody fragments. Unlike conventional workflows that treat enzymatic cleavage and purification as sequential and independent operations, the IPA construct achieves functional integration at the protein engineering level, thereby offering a new strategy for process intensification in antibody fragment preparation. The fusion protein retains the full proteolytic activity of IdeS as well as high-affinity Fc binding mediated by the Protein A domain. Importantly, cleavage assays demonstrated that Fc engagement by the Protein A module does not compromise IdeS activity, even under conditions where most IPA molecules are occupied by Fc fragments generated during the reaction. This observation underscores the effectiveness of the flexible (GGGGA)4 linker in decoupling enzymatic catalysis from affinity binding, allowing simultaneous engagement of a single IgG molecule by both functional domains. The comparable cleavage efficiency observed for human IgG1, IgG2, and IgG4 relative to native IdeS further confirms that domain fusion does not impose significant steric or kinetic constraints on protease function. Beyond its utility as a soluble reagent, a key innovation of this work lies in the immobilization of IPA as an affinity chromatography ligand to establish an on-column cleavage-purification system. Unlike previous analytical-scale online platforms for antibody fragments,14,15 the present work enables one-step preparation and purification of antibody fragments at a preparative scale. In addition, in contrast to existing commercial antibody fragment preparation solutions such as the Genovis FragITTM platform, which require a sequential workflow involving an immobilized IdeS digestion step followed by a separate affinity capture process to remove Fc-containing species, the IPA resin enables cleavage and purification to occur concurrently within a single chromatographic operation. As antibodies are captured via Fc-Protein A interactions, the immobilized IdeS domains catalyze in situ hinge cleavage, releasing F(ab′)2 fragments directly into the flow-through while retaining Fc fragments, residual intact IgG, and the enzyme itself on the column. This molecular-level integration eliminates the need for additional polishing steps and ensures complete removal of protease contamination from the product stream. The practical performance of the IPA resin highlights both its robustness and reproducibility. Across multiple loading and regeneration cycles, the column consistently yielded high-purity F(ab′)2 fragments (>96%) with stable recovery, demonstrating that the fusion protein tolerates low-pH regeneration conditions commonly used in affinity chromatography. The observed yields of 65–76% compare favorably with conventional small-scale IdeS-based workflows, in which multi-step processing and post-digest cleanup are well known to contribute to cumulative yield loss.16 Nevertheless, several limitations should be acknowledged. First, cleavage efficiency toward mouse IgG2a was markedly lower under the tested conditions, consistent with previously reported subclass and species dependence of IdeS activity.4,17 Optimization of reaction conditions or engineering of IdeS variants with expanded substrate scope may help address this limitation. Second, a fraction of F(ab′)2 fragments remained associated with the resin (Figure S11), likely due to weak interactions between exposed variable regions and the Protein A domain. This suggests that further refinement of the Protein A module or linker architecture could improve fragment recovery. Finally, the current study focused on small-scale model systems; future work will be required to evaluate scalability, long-term ligand stability, and performance across a broader range of antibodies and fragment formats. Despite these limitations, the IPA platform offers clear advantages for applications requiring rapid, high-purity antibody fragment generation. It is particularly well suited for early-stage research, high-throughput screening, and structural biology studies, where speed, simplicity, and sample homogeneity are essential. More broadly, this work demonstrates the feasibility of designing multifunctional enzyme-affinity fusion proteins as advanced separation media, suggesting that similar strategies could be extended to other proteases and binding modules to enable integrated bioprocessing solutions. Materials and methods Protein expression and purification DNA sequences encoding Protein A, IdeS, and IdeS-Protein A (each with a C-terminal His-tag) were synthesized and cloned into pET28a vectors for expression in E. coli. For IdeS-Protein A-C, an N-terminal His-tag followed by a TEV cleavage site was added. All proteins were purified by Ni-NTA chromatography (Tofflon, Ni-TED Purose 6 Fast Flow) and polished by SEC (Superdex 75 Increase 10/300 GL). Antibodies were cloned into pcDNA3.1 vectors and expressed in HEK293 cells. Culture supernatants were harvested 6 days post-transfection and purified by Protein A affinity chromatography followed by cation-exchange chromatography (Cytiva, Capto S ImpAct). Eluted proteins were concentrated and buffer-exchanged into phosphate-buffered saline. Size-exclusion chromatography SEC was performed on a Thermo Scientific UltiMate 3000 HPLC system. Samples were centrifuged at 13,000 rpm for 5 min prior to analysis. Ten microgram samples were injected onto a NanoChrom BioCore SEC-300 column (7.8 × 150 mm, 5 μm) at 30°C, with a mobile phase of 50 mM phosphate buffer (pH 7.0) containing 300 mM NaCl at a flow rate of 1.0 mL/min. Detection was at 280 nm. Monomer and high-molecular-weight species percentages were determined by area normalization. Capillary electrophoresis sodium dodecyl sulfate Protein samples (3 μL) were mixed with 5 μL of 250 mM N-ethylmaleimide and diluted to 100 μL with sample treatment buffer (28 mM NaH2PO4, 6.7 mM Na2HPO4, 35 mM SDS, pH 6.3). After mixing and brief centrifugation, samples were heated at 70°C for 10 min, cooled, and centrifuged at 6,000 rpm for 1 min. Supernatant (75 μL) was analyzed on a PA 800 Plus system (Sciex) equipped with a PDA detector. Separation used a bare-fused silica capillary (50 μm i.d. ×30 cm total length, 20 cm effective length) at 25°C, with detection at 220 nm. Binding affinity determination Binding affinity of IdeS-Protein A for human IgG1 was determined by BLI on an Octet 384 system (Pall Life Sciences). Biotin-labeled IdeS-Protein A was loaded onto streptavidin sensors, followed by association with adalimumab (300 s) and dissociation in buffer (300 s). Data were collected at 30°C and analyzed using ForteBio software, fitting to a 1:1 binding model to calculate association and dissociation rates, and KD was calculated using the ratio kd/ka. Preparation of IPA resin Chromatography media (Nanomicro, NWRose4 FF) was centrifuged and the supernatant removed. The media consists of cross-linked 4% agarose microspheres (45–165 μm) and is supplied in an epoxy-activated form. The media was equilibrated three times with 1.2 M sodium sulfate buffer (50 mM sodium phosphate, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 8.8). IdeS-Protein A-C was buffer-exchanged into 50 mM sodium phosphate, 1 mM EDTA (pH 7.5), then mixed with 2 M sodium sulfate solution (in the same buffer, pH 7.5) at a 3:1 volume ratio, and the pH was adjusted to 8.8. The protein mixture was added to the pre-equilibrated media and incubated overnight at 37°C with shaking (180 rpm). Coupling efficiency was monitored by HPLC. Validation of IPA resin for antibody fragment generation The validation experiment of the resin for antibody fragment generation was performed on the SePure SDA030 chromatography system. A chromatography column (Diba Industries, Omnifit EZ Column, 6.6 × 150 mm) was packed with 3.4 mL IPA resin and rinsed with 10 column volumes (CV) of equilibration buffer (20 mM PB, pH 6.0) until the UV280 signal reached 0 mAU and the pH stabilized around 6. The antibody (adalimumab, 2 mg) was then diluted to 0.5 mg/mL using the equilibration buffer and loaded onto the column at a flow rate of 0.2 mL/min. Collection of the flow-through was started when the UV280 signal rose to 10 mAU and was stopped when the signal dropped back to 10 mAU. After the UV signal decreased to approximately 0 mAU, elution was performed at a flow rate of 2 mL/min using elution buffer (50 mM NaAc-HOAc, pH 3.4). Collection of the eluate was started when the UV280 signal rose to 10 mAU and was stopped when the signal dropped back to 10 mAU. Following elution, the column was re-equilibrated with 10 CV of equilibration buffer (20 mM PB, pH 6.0) until the UV280 signal approached baseline and the pH stabilized around 6. Subsequently, the next cycle of loading and elution was initiated. This process was repeated for a total of 5 cycles. The collected flow-through and eluates were analyzed by SEC, and the experimental yield of F(ab′)2 fragments was calculated. Supplementary Material Supplementary material.docx